CEOs of The LYCRA Company and Qore® Join Global Fashion Summit Lineup
The LYCRA Company, a global leader in developing sustainable fibers and solutions for the apparel industry, announced today that its CEO, Gary Smith, is a speaker at the Global Fashion Summit: Copenhagen Edition 2025. He will be joined on stage by Jon Veldhouse, CEO of Qore®, the maker of QIRA®, a next-generation BDO and a key ingredient in bio-derived LYCRA® fiber, which is launching later this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250601837469/en/
LYCRA® brand and QIRA® are principal sponsors of the Global Fashion Summit: Copenhagen Edition 2025. The brands are exhibiting at the event, where they will promote bio-derived LYCRA® fiber made with QIRA®, derived from field corn, to help make fashion more sustainable.
Smith and Veldhouse will discuss the development of this sustainable fiber made from annually renewable field corn during their Fireside Chat: From Farm to Fashion. Their session takes place on Wednesday, June 4, at 3:35 CEST in the DR Concert Hall. The discussion will be moderated by Amy Nguyen, a researcher, writer, and founder of Sustainable & Social.
This is the first time both companies are participating in the Global Fashion Summit, a premier platform focused on sustainability in the fashion industry. The companies have a prominent exhibit space for attendees to learn more about bio-derived LYCRA® fiber made with QIRA®. Here, visitors can be transported to the Qore® site and cornfields in Iowa through a virtual reality experience.
Bio-derived LYCRA® EcoMade fiber will be the world's first large-scale, commercially available renewable elastane. It delivers equivalent performance to the original LYCRA® fiber and serves as a one-to-one replacement with no re-engineering of fabrics, processes, or garment patterns required. The product contains 70 percent renewable content and can potentially reduce the carbon footprint of LYCRA® fiber by up to 44 percent*. The LYCRA Company holds patents related to this renewable fiber in several regions including Europe.
'We're proud to join the Global Fashion Summit for the first time and showcase how collaboration can accelerate a more sustainable future for fashion,' said Gary Smith, CEO of The LYCRA Company. 'Partnering with Qore® has enabled us to scale innovation that is renewable and ready to meet the demands of global fashion brands striving to meet their sustainability goals.'
The newly constructed Qore® site in Eddyville, Iowa, began operating last month and has started producing QIRA®. The company will host a grand opening celebration in July.
'Starting production at our new state-of-the-art facility marks a major step forward—not just for Qore®, but for the entire industry,' said Jon Veldhouse, CEO of Qore®. 'With QIRA® now being made in Iowa from annually renewable field corn, we're turning sustainable innovation into reality and helping our partners bring next-generation materials to market.'
Learn more about this renewable offering by visiting lycra.com/qira.
*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll Americas Engineering Solutions, Inc.
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers' products by offering unique innovations that meet the consumer's need for comfort and lasting performance. Learn more at lycra.com.
About Qore® LLC
Formed through a joint venture by Cargill and HELM AG, Qore® helps leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 86% of greenhouse gas emissions when replacing today's widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance. For more information and inquiries, visit https://www.myqira.com/.
About The Global Fashion Summit
Global Fashion Summit is a leading international forum for sustainability in fashion, presented by Global Fashion Agenda (GFA). Convening major decision makers from across the world, the forum was first launched in 2009 and has become a nexus for agenda-setting discussions and presentations on the most critical environmental, social and ethical issues facing our industry and planet, all intended to spark urgent action and accelerate impact in the industry. Learn more at https://bit.ly/3WVUqCd.
LYCRA® is a trademark of The LYCRA Company.
QIRA® is a trademark of Qore®.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250601837469/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Primo Brands to Participate in a Virtual Fireside Chat at the Barclays 18th Annual Global Consumer Staples Conference
TAMPA, Fla. and STAMFORD, Conn., Aug. 20, 2025 /PRNewswire/ -- Primo Brands Corporation (NYSE: PRMB) ("Primo Brands" or the "Company") today announced that Chief Executive Officer Robbert Rietbroek and Chief Financial Officer David Hass will participate in a virtual fireside chat with Barclays on Thursday, September 4, 2025. The presentation, which will begin at approximately 7:30 a.m. Eastern Time, will be webcast through the investor relations section of Primo Brands' website at and will be archived for replay following the event. For purposes of public disclosure, including this and future similar events, Primo Brands uses the investor relations section of its website as the primary channel for publishing key information to its investors, some of which may contain material and previously non-public information. ABOUT PRIMO BRANDSTM Primo Brands is a leading North American branded beverage company focused on healthy hydration, delivering responsibly sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every U.S. state and Canada. Primo Brands has a comprehensive portfolio of highly recognizable and conveniently packaged branded water and beverages that reach consumers whenever, wherever, and however they hydrate through distribution across retail outlets, away from home such as hotels and hospitals, and food service accounts, as well as direct delivery to homes and businesses. These brands include established "billion-dollar brands" Poland Spring® and Pure Life®, premium brands like Saratoga® and Mountain Valley®, regional leaders such as Arrowhead®, Deer Park®, Ice Mountain®, Ozarka®, and Zephyrhills®, purified brands including Primo Water® and Sparkletts®, and flavored and enhanced brands like Splash Refresher™ and AC+ION®. Primo Brands also has an industry-leading line-up of innovative water dispensers, which create consumer connectivity through recurring water purchases. Primo Brands operates a vertically integrated coast-to-coast network that distributes its brands to more than 200,000 retail outlets, as well as directly reaching consumers through its Direct Delivery, Exchange and Refill offerings. Through Direct Delivery, Primo Brands delivers responsibly sourced hydration solutions direct to home and business customers. Through its Exchange business, consumers can visit approximately 26,500 retail locations and purchase a pre-filled, multi-use bottle of water that can be exchanged after use for a discount on the next purchase. Through its Refill business, consumers have the option to refill empty multi-use bottles at approximately 23,500 self-service refill stations. Primo Brands also offers water filtration units for home and business customers across North America. Primo Brands is a leader in reusable beverage packaging, helping to reduce waste through its multi-serve bottles and innovative brand packaging portfolio, which includes recycled plastic, aluminum, and glass. Primo Brands has a portfolio of over 80 springs and actively manages water resources to help assure a steady supply of quality, safe drinking water today and in the future. Primo Brands also helps conserve over 28,000 acres of land across the U.S. and Canada. Primo Brands is proud to partner with the International Bottled Water Association ("IBWA") in North America, which supports strict adherence to safety, quality, sanitation, and regulatory standards for the benefit of consumer protection. Primo Brands is committed to supporting the communities it serves, investing in local and national programs and delivering hydration solutions following natural disasters and other local community challenges. Primo Brands employs more than 12,000 associates with dual headquarters in Tampa, Florida, and Stamford, Connecticut. For more information, please visit View original content to download multimedia: SOURCE Primo Water Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
23 minutes ago
- Business Wire
Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. ('Sonendo' or the 'Company') (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. 'Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn,' stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'John has been a significant contributor to all those improvements, and we expect he will continue to drive additional operating leverage as the Company continues to execute its plans to achieve profitability. John is a valuable member of the team, and I am excited to see him take on the role of Chief Operating Officer.' In addition to his previous responsibilities overseeing quality, manufacturing, supply chain, and technical services operations, Mr. McGaugh now has oversight of Sonendo's capital and consumables sales teams and commercial operations. Mr. McGaugh has over 20 years overseeing global manufacturing operations. He joined Sonendo in May 2023 and has been instrumental in leading significant operational efficiencies with console assembly and procedure instrument margin contributions. Prior to his time at Sonendo, Mr. McGaugh served as a multi-site operational leader for Abbott Vascular. In addition to his experience at Abbott, Mr. McGaugh has held leadership roles at Boston Scientific and American Medical Systems. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's ability to continue to drive additional operating leverage and/or execute its plans to achieve profitability, whether as a result of Mr. McGaugh or otherwise. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Yahoo
30 minutes ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
